Neuroplasticity in Parkinson's Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age21-75
SponsorUniversity of Minnesota
About this trial
The purpose of this project is to increase our understanding of the early state and temporal evolution of neuroplastic changes in the cortex and subthalamic nucleus (STN) of people with PD, and the relationship of these changes to the emergence and expression of PD motor and non-motor signs. Neurophysiological biomarkers derived from this work may be important for the early detection and prediction of progression of disease. They can also provide the means to assess the efficacy of interventions designed to prevent or slow disease progression.
Eligibility criteria
Qualifiers
Diagnosis of idiopathic PD, as determined by a movement disorders neurologist in accordance with the PD Society Brain Bank diagnostic criteria
Not receiving levodopa or dopamine agonist to treat PD (at baseline)
Able to ambulate independently without the use of an assistive device (e.g. cane) for 50 meters Healthy Controls
Age- (+/- 3 years) and sex-matched to participants with PD
Disqualifiers
Dementia diagnosis and/or a University of California Brief Assessment of Capacity to Consent (UBACC) score and MacCAT-CR score indicating impaired capacity to consent
History of musculoskeletal disorders that significant affect movement of lower or upper limbs as determined at the time of enrollment
History of bipolar disorder, post-traumatic stress disorder or major depressive disorder
Other significant neurological disorders that may affect participation or performance in the study
Trial design
Treatments tested in this trial
- Neuroimaging
- Quantitative assessments
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov